Agentix (AGTX) Cash & Equivalents (2013 - 2026)
Agentix's (AGTX) quarterly Cash & Equivalents came in at $771.0 in Q1 2026, down 82.78% YoY from $4477.0 in Q1 2025, and down 87.95% on a QoQ basis from $6396.0 in Q4 2025.
Agentix (AGTX) Cash & Equivalents (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 14 years of Cash & Equivalents data on file, last reported at $771.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 82.78% year-over-year to $771.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $771.0 (down 82.78% YoY) and the FY2026 annual result came in at $771.0, down 82.78% from the prior year.
- Cash & Equivalents eased to $771.0 in Q1 2026, from $6396.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $27538.0 in Q3 2023 to a low of $189.0 in Q2 2022.
- A 5-year average of $6302.2 and a median of $5601.0 in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents soared 2998.41% — and 2026, when it sank 82.78%.
- Tracing AGTX's Cash & Equivalents over 5 years: stood at $679.0 in 2022, then soared by 412.52% to $3480.0 in 2023, then surged by 137.73% to $8273.0 in 2024, then decreased by 22.69% to $6396.0 in 2025, then slumped by 87.95% to $771.0 in 2026.
- The last three Cash & Equivalents figures came in at $771.0 (Q1 2026), $6396.0 (Q4 2025), and $5601.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 38.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.00 |
| Mar 31, 2026 | 771.00 |
| Dec 31, 2025 | 6,396.00 |
| Sep 30, 2025 | 5,601.00 |
| Jun 30, 2025 | 4,412.00 |
| Mar 31, 2025 | 4,477.00 |
| Dec 31, 2024 | 8,273.00 |
| Sep 30, 2024 | 6,345.00 |
| Jun 30, 2024 | 9,072.00 |
| Mar 31, 2024 | 6,535.00 |
| Dec 31, 2023 | 3,480.00 |
| Sep 30, 2023 | 27,538.00 |
| Jun 30, 2023 | 5,856.00 |
| Mar 31, 2023 | 12,369.00 |
| Dec 31, 2022 | 679.00 |
| Sep 30, 2022 | 2,702.00 |
| Jun 30, 2022 | 189.00 |
| Feb 28, 2022 | 2,442.00 |
| Nov 30, 2021 | 1,237.00 |
| Aug 31, 2021 | 1,768.00 |